UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Troglitazone

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Troglitazone	1.2		Estradiol-17beta-glucuronide	CHO-OATP1B1	Gui, 2008
SLCO1B3	OATP1B3, OATP8	Troglitazone	15.7		Estradiol-17beta-glucuronide	CHO-OATP1B3	Gui, 2008
SLCO1B1	OATP1B1, OATP-C, OATP2, LST-1	Troglitazone		1	Estradiol-17beta-glucuronide	CHO-OATP1B1	Gui, 2009
ABCC3	MRP3	Troglitazone	31		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCC4	MRP4	Troglitazone	61		Estradiol-17beta-glucuronide	Sf9 cell membrane vesicles	Morgan, 2013
ABCB11	BSEP	Troglitazone	16		Glycocholate	BSEP-expressing Sf9 vesicles	Kis, 2009
ABCB11	BSEP	Troglitazone	27.6		Taurochenodeoxycholate	BSEP-expressing Sf9 vesicles	Kis, 2009
ABCB11	BSEP	Troglitazone	9.5		Taurocholate	BSEP-expressing Sf9 vesicles	Kis, 2009
ABCB11	BSEP	Troglitazone	3		Taurocholate	Sf9 cell membrane vesicles	Morgan, 2013

No drug-drug interaction information.